- Home
- ENSC vs SBFM Comparison
ENSC vs SBFM Comparison
Compare ENSC & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- SBFM
- Stock Information
- Founded
- ENSC 2003
- SBFM 2006
- Country
- ENSC United States
- SBFM United States
- Employees
- ENSC N/A
- SBFM N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- SBFM Health Care
- Exchange
- ENSC Nasdaq
- SBFM Nasdaq
- Market Cap
- ENSC 6.4M
- SBFM 6.7M
- IPO Year
- ENSC N/A
- SBFM N/A
- Fundamental
- Price
- ENSC $2.46
- SBFM $1.68
- Analyst Decision
- ENSC
- SBFM Strong Buy
- Analyst Count
- ENSC 0
- SBFM 1
- Target Price
- ENSC N/A
- SBFM $7.00
- AVG Volume (30 Days)
- ENSC 149.6K
- SBFM 65.6K
- Earning Date
- ENSC 11-11-2025
- SBFM 11-04-2025
- Dividend Yield
- ENSC N/A
- SBFM N/A
- EPS Growth
- ENSC N/A
- SBFM N/A
- EPS
- ENSC N/A
- SBFM N/A
- Revenue
- ENSC $7,413,722.00
- SBFM $36,341,741.00
- Revenue This Year
- ENSC N/A
- SBFM $32.20
- Revenue Next Year
- ENSC $1,354.55
- SBFM $32.74
- P/E Ratio
- ENSC N/A
- SBFM N/A
- Revenue Growth
- ENSC 415.58
- SBFM 19.22
- 52 Week Low
- ENSC $1.62
- SBFM $1.17
- 52 Week High
- ENSC $14.67
- SBFM $3.90
- Technical
- Relative Strength Index (RSI)
- ENSC 66.12
- SBFM 67.40
- Support Level
- ENSC $2.35
- SBFM $1.50
- Resistance Level
- ENSC $2.64
- SBFM $1.76
- Average True Range (ATR)
- ENSC 0.16
- SBFM 0.08
- MACD
- ENSC 0.02
- SBFM 0.02
- Stochastic Oscillator
- ENSC 76.79
- SBFM 71.87
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.